gao - 05-984 . washington , d.c.: september 30 , 2005 . influenza pandemic: challenges in preparedness and response . gao - 05- 863t . washington , d.c.: june 30 , 2005 . washington , d.c.: may 26 , 2005 . vaccination is the primary method for preventing influenza and its complications . produced in a complex process that involves growing viruses in millions of fertilized chicken eggs , influenza vaccine is administered each year to protect against particular influenza strains expected to be prevalent that year . experience has shown that vaccine production generally takes 6 or more months after a virus strain has been identified ; vaccines for certain influenza strains have been difficult to mass - produce . after vaccination for the annual influenza season , it takes about 2 weeks for the body to produce the antibodies that protect against infection . according to cdc recommendations , the optimal time for annual vaccination is october through november . because the annual influenza season typically does not peak until january or february , however , in most years vaccination in december or later can still be beneficial . at present , two vaccine types are recommended for protection against influenza in the united states: an inactivated virus vaccine injected into muscle and a live virus vaccine administered as a nasal spray . the injectable vaccine — which represents the large majority of influenza vaccine administered in this country — can be used to immunize both healthy individuals and individuals at highest risk for severe complications , including those with chronic illness and those aged 65 years and older . the nasal spray vaccine , in contrast , is currently approved for use only among healthy individuals aged 5 to 49 years who are not pregnant . for the 2003 – 04 influenza season , two manufacturers — one with production facilities in the united states ( sanofi pasteur ) and one with production facilities in the united kingdom ( chiron ) — produced about 83 million doses of injectable vaccine , which represented about 96 percent of the u.s. vaccine supply . a third u.s. manufacturer ( medimmune ) produced the nasal spray vaccine . for the 2004 – 05 influenza season , cdc and its advisory committee on immunization practices ( acip ) initially recommended vaccination for about 188 million people in designated priority groups , including roughly 85 million people at high risk for severe complications . gao - 05-177t . washington , d.c.: november 18 , 2004 . infectious disease preparedness: federal challenges in responding to influenza outbreaks . gao - 04-1100t . washington , d.c.: september 28 , 2004 . public health preparedness: response capacity improving , but much remains to be accomplished . gao - 04-458t . washington , d.c.: february 12 , 2004 . flu vaccine: steps are needed to better prepare for possible future shortages . gao - 01-786t . washington , d.c.: may 30 , 2001 . flu vaccine: supply problems heighten need to ensure access for high - risk people . gao - 01-624 . washington , d.c.: may 15 , 2001 . influenza pandemic: plan needed for federal and state response . gao - 01-4 . washington , d.c.: october 27 , 2000 .